Merck & Co. Strengthening Its Strong Position In Immuno-Oncology

Additional data presented at ASCO support earlier use of Keytruda in key settings like first-line lung and bladder cancers and approval in new indications like triple-negative breast and gastric cancers. Competitor setbacks also clear the stage for Merck.

Digital illustration of Cancer cell in colour background

This year's American Society of Clinical Oncology meeting left Merck & Co. Inc. in an even more attractive immuno-oncology position than before – with additional data helping to secure the lead for its PD-1 inhibitor Keytruda in key indications like lung and bladder cancer, where competitors have fallen back, as well as promising debuts in new tumor types like breast and gastric tumors.

Merck stressed during a June 5 investor briefing at ASCO that it is working to establish Keytruda as a foundation...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Immuno-oncology

CEO Underlines AstraZeneca’s Increasingly US-Centric Growth Plans

 

Its multibillion dollar investment demonstrates the importance of the US to AstraZeneca, with half of its targeted $80bn revenues by 2030 set to come from the country, Pascal Soriot said as it presented strong second-quarter results.

Dispatch Uses ‘Flare’ To Send CAR-Ts To Solid Tumors

 

With $216m in initial funding, the newly launched company is aiming to develop a cell therapy-based universal immuno-oncology option for solid tumor indications.

Chinese Biotechs Sweep ADC Plus PD-(L)1/VEGF Bispecific Combos Into Phase II

 

Chinese firms Junshi, Minghui and RemeGen rank among the world’s few players progressing antibody-drug conjugates combined with PD-(L)1/VEGF bispecific antibodies in Phase II trials for various cancers.

Sino Biopharm Scoops LaNova In Chinese Pharma’s Biggest Biotech Buyout So Far

 

Sino Biopharm will pay almost $1bn to acquire what target LaNova’s CEO described as an “exploding” pipeline, which includes six clinical-stage candidates in the oncology area.

More from Anticancer

Analysts Not Impressed With Adaptimmune’s Survival Attempts

 
• By 

The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.

Celcuity Preps For Potentially Huge Market After Phase III Gedatolisib Win

 

The biotech announced positive results in the PIK3CA wild-type population in second-line HR+/HER2- breast cancer for its PAM inhibitor.

GSK’s Blenrep US Setback Could Go From Bad To Worse

 

With a US approval any time soon now looking unlikely, analysts are revising Blenrep’s peak sales guidance downwards.